Pulmonx

Pulmonx Corporation is a medical technology company that specializes in minimally invasive devices for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company's core offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema; the Chartis Pulmonary Assessment System, which assesses collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography images to aid in treatment planning. Pulmonx's solutions are intended for patients who remain symptomatic despite medical management and are either not candidates for or do not wish to pursue surgical options. The Zephyr Valve has received FDA pre-market approval and is supported by extensive clinical evidence demonstrating its benefits. Pulmonx serves a global market, with significant operations in the United States and various international regions, and has made a notable impact by treating thousands of patients with its innovative technology.